Lv3
320 积分 2023-08-25 加入
Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations
18天前
已完结
Adjuvant Immunotherapy Should Be Used in Patients With Non-Small Cell Carcinoma With a Pathologic Complete Response to Neoadjuvant Immunotherapy
23天前
已完结
Revisiting neoadjuvant therapy in non-small-cell lung cancer
24天前
已完结
Reconsidering adjuvant and perioperative immune-checkpoint inhibition: de-escalation, expansion and personalization
24天前
已完结
Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR -Variant Non–Small Cell Lung Cancer
30天前
已完结
Improving neoadjuvant and perioperative therapy in non-small-cell lung cancer
1个月前
已完结
LEAP-008: Lenvatinib Plus Pembrolizumab for Metastatic NSCLC That Has Progressed After an Anti–Programmed Cell Death Protein 1 or Anti–Programmed Cell Death Ligand 1 Plus Platinum Chemotherapy
1个月前
已完结
Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study
1个月前
已完结
Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial
2个月前
已完结
皖公网安备34019202002308
